Double counting and the reporting of cost per event avoided

Clinical Therapeutics

Volumn 28, Issue 4, 2006, Pages 602-603

  Mullins, C Daniel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCULATION; CONSUMER; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; EDITORIAL; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HUMAN; MEDICAL SOCIETY; MEDICALLY UNDERSERVED; OUTCOME ASSESSMENT; PHARMACOECONOMICS; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; ECONOMICS, PHARMACEUTICAL; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 33646889081     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.04.002     Document Type: Editorial

References (12)

1. Grabowski H.G., and Mullins C.D. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med 45 (1997) 535-544
2. Johannesson M. Avoiding double-counting in pharmacoeconomic studies. PharmacoEconomics 11 (1997) 385-388
3. Luce B.R., Manning W.G., Siegel J.E., and Weinstein M.C. Estimating costs in cost-effectiveness analysis. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York, NY 176-213
4. Weinstein M.C., Siegel J.E., Gold M.R., et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 276 (1996) 1253-1258
5. Rothermich E.A., and Pathak D.S. Productivity-cost controversies in cost-effectiveness analysis: Review and research agenda. Clin Ther 21 (1999) 255-267
6. Johannesson M., and Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ 7 (1998) 1-7
7. Liljas B. How to calculate indirect costs in economic evaluations. PharmacoEconomics 13 (1998) 1-7
8. Brouwer W.B., Koopmanschap M.A., and Rutten F.F. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 6 (1997) 253-259
9. Brouwer W.B., Koopmanschap M.A., and Rutten F.F. Productivity costs in cost-effectiveness analysis: Numerator or denominator: A further discussion. Health Econ 6 (1997) 511-514
10. Weinstein M.C., Siegel J.E., Garber A.M., et al. Productivity costs, time costs and health-related quality of life: A response to the Erasmus Group. Health Econ 6 (1997) 505-510
11. Reed S.O., Mullins C.D., and Magder L.S. Cost effectiveness of abciximab during routine medical practice. PharmacoEconomics 18 (2000) 265-274
12. Johannesson M., Jonsson G., and Karlsson G. Outcome measurement in economic evaluation. Health Econ 5 (1996) 279-296